A Study to Evaluate the Efficacy and Safety of AKCEA-TTR-LRx in Participants with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

Overview

About this study

The purpose of this study is to evaluate the effectiveness and safety of AKCEA-TTR-LRx after administration for 65 weeks to patients with hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN), as compared to the NEURO-TTR trial (NCT01737398).

For more information, please visit http://www.neuro-ttransform.com/.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Aged 18 to 82 years at the time of informed consent.
  • Females must be non-pregnant and non-lactating, and either surgically sterile or post-menopausal or abstinent.
  • Males must be surgically sterile or, abstinent or, if engaged in sexual relations with a woman of child-bearing potential, the subject or the subject's non-pregnant female partner must be using a highly effective contraceptive method.
  • Diagnosis of hereditary transthyretin-mediated polyneuropathy as defined by meeting all 3 of the following:
    • Stage 1 or Stage 2 Familial Amyloid Polyneuropathy (FAP) or Coutinho Stage.
  • Documented genetic mutation in the TTR gene.
  • Symptoms and signs consistent with neuropathy associated with transthyretin amyloidosis, including NIS ≥ 10 and ≤ 130.

Exclusion Criteria:

  • Clinically-significant (CS) abnormalities in medical history, screening laboratory results, physical or physical examination that would render a subject unsuitable for inclusion, including but not limited to abnormal safety labs.
  • Karnofsky performance status ≤ 50.
  • Other causes of sensorimotor or autonomic neuropathy (e.g., autoimmune disease), including uncontrolled diabetes.
  • Prior liver transplant or anticipated liver transplant within 1-yr of Screening.
  • New York Heart Association (NYHA) functional classification of ≥ 3.
  • Acute coronary syndrome within 6 months of screening or major surgery within 3 months of Screening.
  • Other types of amyloidosis.
  • Have any other conditions, which, in the opinion of the Investigator or Sponsor would make the subject unsuitable for inclusion, or could interfere with the subject participating in or completing the Study.
  • Current treatment with any approved drug for hereditary TTR amyloidosis such as Vyndaqel® / Vyndamax™ (tafamidis), Tegsedi™ (inotersen), Onpattro™ (patisiran), off-label use of diflunisal or doxycycline, and tauroursodeoxycholic acid (TUDCA). If previously treated with Vyndaqel® / Vyndamax™, diflunisal or doxycycline, and TUDCA, must have discontinued treatment for at least 2 weeks prior to Study Day 1.
  • Current or previous treatment with Tegsedi™ (inotersen) or Onpattro™ (patisiran) or other oligonucleotide or RNA therapeutic (including siRNA). This exclusion criterion does not apply to COVID-19 mRNA vaccinations.

Eligibility last updated 1/25/22. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Julie Khoury, M.D.

Closed for enrollment

Contact information:

Machiko Anderson R.N.

(480) 301-4302

Anderson.Machiko@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20490394

Mayo Clinic Footer